Table 2 Baseline details of pivotal studies included in the review for planned oocyte cryopreservation
Author, year (ref) | Type of study | Study population | Sample size | Mean age at cryopreservation in years | Stimulation Protocol | Mean number of mature oocytes (MIIs) cryopreserved |
|---|---|---|---|---|---|---|
Blakemore et al., 2021 [29] | Retrospective | ≥ 1 POC | 231 patients (280 cycles) | 38.2 (range 23-45) | Antagonist, LDL, Microflare | < 35: 13.8 35-37: 11.5 38-40: 9.0 41-42: 9.9 > 42: 6.8 |
Cobo et al., 2018 [7] | Retrospective | POC and MOC | 6362 patients ● 5289 POC (7044 cycles) ● 1073 MOC (1172 cycles) | POC: 37.2 ± 4.9 MOC: 32.3 ± 3.5 | Antagonist Agonist Antagonist+letrozole | POC: 7.3 ± 11.3 per cycle MOC: 8.7 ± 2.1 per cycle |
Doyle et al., 2016 [30] | Retrospective | Women undergoing IVF/ICSI for infertility compared to POC + MOC | 128 POC + MOC cycles 1283 vitrified/warmed oocytes 2963 fresh ICSI cycles in infertile couples | POC + MOC: 34.9 Fresh: 35.5 | Antagonist, Microflare | POC + MOC: 8.0 Fresh: 10.1 |
Garcia-Velasco et al., 2013 [31] | Retrospective | POC and MOC | 1035 patients (1080 cycles) ● 560 POC (725 cycles) ● 475 MOC (355 cycles) | POC: 36.7 ± 4.2 MOC: 31.9 ± 5.1 | Antagonist Antagonist+letrozole | POC: 9.9 per patient MOC: 8.5 per patient |
Goldman et al., 2017 [32] | Retrospective, modeling study | First fresh male-factor and/or tubal factor only autologous ICSI cycles and egg donation cycles | Male factor and or tubal factor (n = 466) Egg donation (n = 54) | Autologous: NA Donor: 28.5 | NA | ≤ 35: 13.7 ± 7.5 36: 14.6 ± 7.4 37: 11.8 ± 6.9 38: 8.5 ± 5.7 39: 8.5 ± 4.9 40: 8.3 ± 5.6 41: 9.7 ± 4.2 42: 10.3 ± 6.9 > 42: 6.9 ± 5.6 |
Gürtin et al., 2019 [33] | Retrospective | POC and non-POC | 129 patients ● 46 POC (64 cycles) ● 83 non-POC (96 cycles) | POC: 37.7 Non-POC: 37.2 | NA | POC: 9.3 per cycle Non-POC: 6.1 per cycle POC: 14.0 per patient Non-POC: 11.2 per patient |
Leung et al., 2021 [34] | Retrospective | POC < 38 versus ≥38 years old | 921 patients (1265 cycles) | 38.1 ± 1.8 (range 34-42) | NA | < 38: 18.4 ± 9.2 ≥38: 15.2 ± 7.7 per patient |
Maslow et al., 2020 [35] | Retrospective | ≥ 1 POC | 1241 patients (1799 cycles) | 35.6 ± 3.26 | Antagonist, Microflare | 1st cycles (n = 1241): ≤ 35: 15.41 ± 9.53 35-37: 12.12 ± 8.26 38-40: 9.75 ± 7.72 41-42: 7.25 ± 6.76 > 42: 6.12 ± 4.73 2nd cycles (n = 401): ≤ 35: 10.87 ± 7.74 35-37: 9.60 ± 6.44 38-40: 7.84 ± 4.84 41-42: 8.12 ± 6.90 > 42: 4.30 ± 2.95 |
Nagy et al., 2017 [36] | Prospective, phase IV, multicenter, observation registry | First cycles using thaw/warmed cryopreserved (slow freeze & vitrification) oocytes (autologous or donor) | 193 patients | Slow freeze: 25.1 ± 2.7 (range 20-31) Vitrified: 26.0 ± 2.8 (range 21-31) | NA | NA |
Wafi et al., 2020 [37] | Retrospective, survey | POC | 138 completed surveys | 35.7 (range 24-42) | NA | 17.6 |
Wennberg et al., 2018 [38] | Retrospective | POC | 254 patients | 36.9 (range 23-43) | NA | 7.6 |